Plasma renin activity-guided strategy for the management of hypertension

Pharmacotherapy

Volumn 32, Issue 5, 2012, Pages 446-455

  Olson, Nicole ^a   DeJongh, Beth ^b   Hough, Augustus ^a   Parra, David ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b His research interests involve social media and political engagement   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Hypertension; Hypertension treatment; Low renin hypertension; Plasma renin activity; Renin Angiotensin system; Salt sensitive hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LABETALOL; PLACEBO; PROPRANOLOL; RENIN INHIBITOR; SPIRONOLACTONE; TEPROTIDE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; HYPERTENSION; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PATIENT CODING; PLASMA RENIN ACTIVITY; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; TREATMENT DURATION; TREATMENT PLANNING;

HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84864621351     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01031.x     Document Type: Review

References (36)

1. Centers for Disease Control and Prevention. Vital signs: Prevalence, treatment, and control of hypertension -United States, 1999-2002 and 2005-2008. MMWR 2011;60:103-8.
2. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension 2003;42:1206-52.
3. Cushman WC, Ford CE, Cutler JA, et al. for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-404.
4. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14: 186-94.
5. Laragh JH. Vasoconstriction-volume analysis for understanding and treating Hypertension: The use of renin and aldosterone profiles. Am J Med 1973;55:261-74.
6. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14: 491-503.
7. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14:733-42.
8. Egan BM, Basile JN, Rehman SU, et al. Plasma renin testguided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: A randomized controlled trial. Am J Hypertens 2009;22:792-801.
9. Furberg CD. Treatment of hypertension: A failing report card. Am J Hypertens 2009;22:1-2.
10. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003;16:407-15.
11. Obarzanek E, Proschan MA, Vollmer WM, et al. Individual blood pressure responses to changes in salt intake. Results from the DASH-Sodium Trial. Hypertension 2003;42:459-67.
12. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20:587-97.
13. Sealey JE, Parra D, Rosenstein R, Laragh JH. "Effective" plasma renin activity: A derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010;55:e16.
14. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010;23:1031-7.
15. Furberg CD. Renin-guided treatment of hypertension: Time for action. Am J Hypertens 2010;23:929-30.
16. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991;37:1811-9.
17. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14: 603-9.
18. Turner ST, Schwartz GL, Chapman AB, et al. Plasma renin activity predicts blood pressure responses to b-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010;23:1014-22.
19. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14:296-304.
20. Brown M. Heterogeneity of blood pressure response to therapy. Am J Hypertens 2010;23:926-8.
21. Laragh J, Baer L, Brunner H, Buhler FR, Sealey JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972;52:633-52.
22. Dickerson J, Hingorani A, Ashby M, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
23. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans -Consensus statement of the hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-41.
24. Preston R, Materson B, Reda D, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 1998;280: 1168-72.
25. Gupta A, Poulter N, Dobson J, et al. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT trial. Am J Hypertens 2010;23:1023-9.
26. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: Their wide range and Lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004;17:1-7.
27. Trenkwalder P, James GD, Laragh JH, Sealey JE. Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Am J Hypertens 1996;9:621-7.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 2981-97.
29. Blumenfeld JD, Laragh JH. Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998;11:894-6.
30. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-75.
31. Sealey JE, Laragh JH. Using plasma renin (PRA) testing to design follow up drug treatment strategies in hypertensive patients already taking antirenin drugs. Am J Hypertens 2009;22:950.
32. Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-hour blockade of the renin-Angiotensin system: A high dose of a long-Acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005;78:501-7.
33. Pimenta EKKG, Oparil S, Aban I, Husain S, Dall'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial. Hypertension 2009;54:475-81.
34. Holdiness A, Monahan K, Minor D, de Shazo RD. Renin angiotensin aldosterone system blockade: Little to no rationale for ACE inhibitor and ARB combinations. Am J Med 2011;124:15-9.
35. Alderman MH. A clinical trial of renin profiling in selection of initial antihypertensive drug. In: Clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Available from http://clinicaltrials. gov/ct2/show/NCT00834600. NLM Identifier: NCT00834600. Accessed August 8, 2011.
36. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content and renin-Angiotensin vasoconstriction to long-Term blood pressure. Am J Hypertens 2011;24:1164-80.